Program 2018

September 10th - 11th, San Francisco, CA

7:30 AM - 8:20 AM

Registration & Refreshments

8:20 AM - 8:25 AM

Chair’s Opening Remarks

8:25 AM - 9:00 AM - Keynote

Device Development

Challenges and Opportunities in Combination Product Design, Development and Use

Steve Bowman, Device Program Lead , Shire

  • Importance of coupling device design with drug formulation
  • Main challenges of designing user friendly devices

9:00 AM - 9:05 AM

Please Move to your Next Session

9:05 AM - 9:40 AM - Case Studies

Small Molecules

Artificial Gut Simulator: A Step Closer to In-Vitro In-Vivo Correlation?

Helen Hao Hou, Scientist Small Molecule Pharmaceutical Sciences , Genentech

  • Conventional dissolution apparatus is often neither optimal nor satisfactory for differentiating the drug release performance of formulations and predicting oral bioavailability
  • The need to integrate dissolution and absorption has become increasing apparent
  • A novel apparatus to maintain absorptive sink conditions with a large surface area-to-volume ratio of absorptive surface was developed to conduct simultaneous dissolution and absorption testing
  • The system has been tested and optimized with a model drug, Ketoconazole, to obtain the biorelevant absorption rate constant, ka

Biologics

Characterization of adsorbed vaccine formulation (1)

Marina Kirkitadze, Deputy Director, Head of Biophysics and Conformation Unit, Analytical R&D Biochemistry, Sanofi Pasteur

  • Characterization of combination vaccines comprised of several antigens in a single formulation.
  • Scanning electron microscopy (SEM) and X-ray photoelectron spectroscopy are showcased to examine morphology and size
  • Use of nanoDSF and FTIR spectroscopy for lean material characterisation
  • Studying structure and stability of adsorbed vaccine formulation.

9:40 AM - 9:45 AM

Please Move to your Next Session

9:45 AM - 10:20 AM - Case Studies

Small Molecules

Physiologically Based Pharmacokinetic (PBPK) Modelling of Oral Absorption

Tao Zhang, Principal Scientist Drug Product Design- Molecular Pharmaceutics Pharmaceutical Sciences Small Molecules, Pfizer

  • Application in early pharmaceutical development
  • Role of physicochemical characterization
  • Relating physicochemical characterization to early pharmaceutical development

Device Development

Common Pitfalls in Developing Combination Products and Medical Devices

Scott Brown, Device Development Lead & Executive Director, Merck

  • Fundamental steps in development
  • How devices and combination products fail and steps to avoid failure
  • Project and people related issues

10:20 AM - 11:20 AM

iSolve & Networking Break

11:20 AM - 11:55 AM - Solution Spotlights

Small Molecules

Session TBC

Quotient.jpg

Biologics

Session TBC

Unchained Labs.jpg

11:55 AM - 12:00 PM

Please Move to your Next Session

12:00 PM - 12:35 PM - Case Studies

Small Molecules

Maximize the Potential of Discovery: Early Utilization of Enabling Technology

Richard Hu, Senior Formulations Scientist, Curis Inc.

Delivery of poorly soluble compound has become a major challenge in the pharmaceutical industry, especially in discovery. Many enabling formulation technologies can help to improve the solubility of these drug candidates. However, every compound/project is unique. Take away the best formulation strategy and technique to use that is compound value appropriate, development phase appropriate.

Biologics

Application of High Throughput and Automated Workflows to Large Molecule Formulation and Process Development

Nitin Rathore, Director, Process Development , Amgen

  • As the design space for formulation design becomes more complex and the need for accelerated product development more urgent, traditional approaches do not provide a sustainable means to handle such challenges.
  • Modern development tools that minimize material requirements and maximize use of automation can help overcome these challenges and provide a differentiating capability to rapidly explore large formulation design spaces for novel modalities.
  • Case studies will be presented demonstrating application of these technologies to tackle various drug product development challenges. New approaches to data analysis and visualization leading to effective decision-making will also be covered.

12:35 PM - 1:35 PM

Networking Lunch

Lunch & Learn Round Table with Solvay USA

Ganesh Sanganwar, Principal Engineer R&I, Technology Center, Solvay USA

 

Docusate Sodium: A Multifunctional Excipient for Drug Bioavailability Improvement

Abstract:

Docusate sodium has been used as a pharmaceutical grade excipient for a long time thanks to its unique and versatile properties: wetting agent for poorly soluble APIs, tablet disintegration accelerator, dispersing agent for micro suspensions and emulsifier for creams and gels.

Continuous research is now also exposing its strong performance in advanced solubalization techniques. 

 

This presentation will highlight new applications of Docusate Sodium for drug bioavailability challenges

* Re-explore its wetting, dispersing, and emulsifying properties 

* Research and demonstrate new applications as an excipient for poorly soluble APIs

* Docusate as counter-ion for biopharmaceutical formulation development.

1:35 PM - 2:10 PM - Solution Spotlights

Small Molecules

Session TBC

Biologics

Formulation of Hard-to-Stabilize Biopharmaceuticals

Dr Phil Morton, Chief Technology Officer, Albumedix

  • Recombumin® for the formulation of next generation therapeutics: While in many cases the use of sugars, amino acids and detergents are sufficient there are a number of more challenging biologics where traditional approaches still fail or are suboptimal.
  • Recombumin® the importance of a controlled process:  The lack of endogenous ligands guarantees batch-to-batch consistency and consequently performance reproducibility. Depending on the mechanism of albumin stabilisation we would expect a different influence of excipients, buffer components and, in case of serum derived HSA by endogenous ligand present. 
  • An example is the cryopreservation of stem cells: the viability of the stem cells was kept above the set release criteria for longer using AlbIX compared to HSA.

2:10 PM - 2:15 PM

Please Move to your Next Session

2:15 PM - 2:50 PM - Case Studies

Small Molecules

Impact of Method of Preparation on the Mechanical Properties of Amorphous Solid Dispersions

Karthik Nagapudi, Senior Scientist, Group Leader Solid State Characterization, , Genentech

  • Overview of methods used to make amorphous materials
  • How method of preparation impacts downstream processing of amorphous solids
  • Use of Resonant acoustic mixing in making amorphous dispersions
  • Mechanical characterization of amorphous solids

Biologics

Continuing Challenges for mAb Formulations

Rahul Sunder Rajan Kaushik, Director, Amgen

  • Stabilising protein formulations
  • Designing formulations with environmental and chemical weaknesses in mind

2:50 PM - 3:50 PM

iSolve & Networking Break

3:50 PM - 4:25 PM - Solution Spotlights

Small Molecules

Twin-Screw Melt Granulation of Thermally Labile Drug: Effect of Processing Conditions

Feng Zhang, Assistant Professor, University of Texas at Austin

University of texas.png

foster.jpg

 

  • Processing temperature and reduction of GABA particle size during granulation are significant factors that can affect the chemical stability of GABA.
  • Small particle size of HPC can cause higher degradation due to higher surface area in contact with GABA particles.
  • Processing parameters (screw speed and feed rate) should be optimized to achieve the balance between improving compaction properties but still maintaining chemical stability of GABA.

Biologics

Session TBC

Gore.png

4:25 PM - 4:30 PM

Please Move to your Next Session

4:30 PM - 5:05 PM - Case Studies

Small Molecules

Challenges and Opportunities of Development of Salts of Weak Bases

Anand Sistla, Associate Research Fellow, Pfizer

Salts present a unique opportunity at fixing solubility/dissolution related exposure and/or solid form related challenges. However the drive to progress molecules with low basic pKa (to address safety concerns) in the discovery setting increases risks associated with the design of a robust solid dosage form (namely disproportionation to the base as drug substance or drug product).  Relationship between pKa, pHmax, and salt disproportionation will be discussed.  How to assess this risk and mitigation strategies will be presented

Biologics

Development of different delivery platforms for Biologics

Amish Patel, Director, Product Development , PaxVax

Image result for paxvax

  • Unlike conventional formulation development, delivery platform and late stage formulation focus more on the control of delivery technology for dosage forms. Conditions to keep the desired potency of drug/biologic before and during the administration is equally important.
  • Poor delivery platform will causes significant potency loss of drug/biologic during the administration no matter how great of shelf-life the product has.
  • Scientists working in the formulation field should consider the delivery route as a critical factor in developing their product and design the formulation and delivery study to support it or could see failure in the animal study, clinical study and impact the future of the project

5:05 PM - 5:10 PM

Please Move to your Next Session

5:10 PM - 5:45 PM - Keynote

Biologics

Challenges & Opportunities for Delivering Biologics Drugs Orally and by Inhalation

Rakesh Dixit, Vice President, R&D , Medimmune

medimmune logo.png

  • Unmet medical needs of patients with chronic use biologics
  • Transforming the chronic delivery of biologics
  • Opportunities of delivering oral biologics: innovations in technologies
  • Inhaled biologics: scientific and technological challenges and innovations

5:45 PM - 5:55 PM

Chair’s Closing Remarks and End of Day 1

5:55 PM - 7:00 PM

Evening Drinks Reception

8:00 AM - 8:30 AM

Registration & Refreshments

8:30 AM - 8:35 AM

Chair’s Opening Remarks

8:35 AM - 9:10 AM - Keynote

Technology & Innovation

In What Direction is the Drug Delivery Technology Space Moving?

Anand Subramony, Vice President New Product Technologies, MedImmune

medimmune logo.png

  • Evaluating how fast the delivery technology field has evolved until now – are there limiting factors to its continued development?
  • What is the potential of less-traditional delivery routes such as nasal and ocular delivery?
  • Discussing the future of evolving areas including polymer technologies, auto injectors, microneedles etc.
  • Looking retrospectively, has the industry done all it can until now to maintain the R&D paradigm?

9:15 AM - 9:50 AM - Case Studies

Small Molecules

Application of Innovative technologies in Drug Product Development– Preclinical through Commercialization

Indrajit Ghosh, Associate Director, Senior Principal Scientist, Celgene

Celgene.png

 

  • Challenges on Drug Product Development and need for innovative technologies
  • Overview on Innovative technologies – such as Melt Extrusion, Nanotechnology…
  • Few case studies to demonstrate how the innovative technologies were used for development and commercialization using Quality by Design

Device Development

Understanding the Changing needs for Combination Products and Digital Health

Andrew M. Ratz, Senior Director, Delivery, Device and Connected Solutions, Eli Lilly and Company

Lilly.png

 

The presentation will be focused in the areas of protein drug delivery, device design and development and the increasing importance of software/connectivity for future delivery devices.

9:50 AM - 9:55 AM

Please Move to your Next Session

9:55 AM - 10:30 AM - Solution Spotlights

Small Molecules

Session TBC

capitsol.png

Biologics

Choosing the Correct Self-Injection System for Large Molecule

Roquette.jpg (1)

 

  • Session TBC

10:30 AM - 11:30 AM

iSolve & Networking Break

11:30 AM - 12:05 PM - Case Studies

Biologics

Developing Novel Nanocarriers for Improved Drug Targeting

Seungpyo Hong, Professor Pharmaceutical Sciences and Principal Investigator at the Hong Research Group, University of Wisconsin-Madison

University of Wisconsin.png

  • Controlling biological interactions of polymers with cells at the nano-scale
  • Targeting drugs at cancer cells

Device Development

Electronically-Controlled Meshless Pocket-Size Ultrasonic Inhalers

Chen S. Tsai, Chancellor’s Professor Department of Electrical Engineering and Computer Science, University of California, Irvine

  • First, we describe: (1) the architecture of our silicon-based MFH nozzle and its excitation of megahertz (MHz) Faraday waves in the liquid (medicine) layer sitting on the nozzle end face, and (2) the requisite drive power for droplet ejection and drive frequency for desired droplet diameter.
  • Second, we present data demonstrating the realization of low-drive power pocket-size prototype inhalers and their uses for nebulization of a variety of common and experimental pulmonary drugs with desirable aerosol characteristics.
  • Finally, we discuss the new inhaler’s additional unique capabilities, including simultaneous aerosolization of multiple drugs for combination therapy and the potential for incorporation of IOT technology for enhanced functionality.

12:05 PM - 12:10 PM

Please Move to your Next Session

12:10 PM - 12:45 PM - Solution Spotlights

Small Molecules

Session TBC

Biologics

Session TBC

BDD Logo.png

  • Session TBC

 

 

12:45 PM - 1:45 AM

Networking Lunch

Lunch.png

1:45 PM - 2:20 PM - Case Studies

Small Molecules

Panel Discussion: Oral Films – Where We Are and Where We Are Going? (1)

Zhengming (Jimmy) Chen, Senior Director, Pharmaceutical Science, Shionogi

shionogi.jpg

Technology & Innovation

Nanostructured Devices for Therapeutic Delivery

Tejal Desai, Professor & Chair Department of Bioengineering and Therapeutic Sciences, University of California San Francisco

ucsf.png

 

Therapeutic peptides, proteins, and macromolecular drugs represent highly efficacious approaches for the pharmacologic treatment of human diseases.  However, current administration of such drugs continues to be bolus injection which is inconvenient, painful and can lead to variable dosing.  In this talk, I will discuss nanoporous materials that can be used to deliver proteins to the eye as well as  nanostructured surfaces that enhance the permeability of macromolecules across epithelial cells in response to direct contact. New systems that can deliver proteins and peptides in a stable and controlled manner will have great potential to impact therapeutic development in the future

2:20 PM - 2:25 PM

Please Move to your Next Session

2:25 PM - 3:05 PM - Solution Spotlights

Small Molecules

Session TBC

patheon.png (1)

Biologics

Oral Delivery of Hydrophobic Drugs Using Mixed Micelles

  • Improving bioavailability through mixed micelle formulations
  • PEGylation stabilisation of mixed micelles
  • Mucus penetration through endothelial cells by PEGylated mixed micelles                         

3:05 PM - 3:10 PM

Please Move to your Next Session

3:10 PM - 3:45 PM - Case Studies

Small Molecules

Designing Robust tablet formulas through DOE (Design of Experiment)

Tian Hao, Principal Scientist, Pharmavite LLC

Pharmavite.jpg

  • Resiliance to raw material variation
  • Resiliance to production variations

Small Molecules

Enabling Dry Powder Inhalation Discovery Compounds for Lung Delivery

Ajit Narang, Senior Scientist, Genentech

genentech.png

  • TBC

3:45 PM - 4:20 PM - Case Studies

Small Molecules

Solubilization of a Poorly Soluble Drug with Combination of In-Vitro Dynamic Flow and In-Vivo Rabbit Ear to Identify Parenteral Formulation

Yingqing Ran, Senior Scientist, Genentech

Phlebitis of a parental formulation is one of the main concerns for patient compliance.  It has two major causes, one is the physical precipitation of the compound in blood stream after administration, and another one is chemically irritation due to the compound chemical entity.

In this study, the phlebitis issue of phase I formulation of compound A was due to its poor solubility. Physical precipitation occurred after formulation intravenous injection. In order to minimize precipitation induced phlebitis, pH combination with cosolvents, surfactants, and Cyclodextrins were used to screen the formulation.  L-lactic acid and D-Glucuronic acid are the two counter ions show better solubility of compound A. Both hydroxyl- β-cyclodextrin (HP-β-CD) and sulfobutylether- β-cyclodextrin (SBE- β-CD) have shown further enhancement of the solubility combining with either lactic acid or glucuronic acid. An in vitro dynamic precipitation and an in vivo rabbit ear models have been used to investigate the potential of precipitation and phlebitis of the promising new formulations, there is a correlation between in vitro and in vivo findings. Based on both in vitro and in vivo data, the formulation composed of 40% SBE--β-CD, 50mM Glucuronic acid, and 13mg/ml compounds A has shown significant improvement of phlebitis compared to phase 1 formulation.

Biologics

A Case Study On Our Ebola Vaccine Journey

Jeffrey Blue, Director, Vaccine Drug Product Development, Merck

merck.png

  • Rapid product development and testing
  • Ensuring safety while expediting testing
  • Lessons for future outbreaks

4:20 PM - 4:55 PM - Keynote

Device Development

How Will the Future Look for Next Generation Devices?

Ravi Gopalakrishnan, Head of Mobility, Chief Technology Officer Office, AstraZeneca

astra Zeneca.png

 

  • New materials
  • Improved human factor engineering
  • Connectivity and integration into wider healthcare system

4:55 PM - 5:00 PM

Chair’s Closing Remarks and End of Conference